A recent and innovative clinical study, published in 2019 by Bodet-Milin et al., reported high tumor uptake and increased contrast imaging using pre-targeted anti-CEA immuno-PET in patients with metastatic MTC [47,48]. This evidence concerns the gene CEACAM3 and medullary thyroid gland carcinoma.